OQS
FATE icon

Occudo Quantitative Strategies’s Fate Therapeutics FATE Stock Holding History

Occudo Quantitative Strategies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-98,452
Closed -$561K – 1091
2023
Q1 		$561K Sell
98,452
-67,061
-41% -$405K 0.05% 481
2022
Q4 		$1.67M Buy
165,513
+127,062
+330% +$2.39M 0.19% 156
2022
Q3 		$862K Sell
38,451
-54,536
-59% -$1.58M 0.07% 463
2022
Q2 		$2.3M Buy
+92,987
New +$2.57M 0.19% 144
2021
Q2 		– Sell
-3,034
Closed -$250K – 938
2021
Q1 		$250K Sell
3,034
-2,731
-47% -$262K 0.05% 553
2020
Q4 		$524K Buy
+5,765
New +$358K 0.16% 227

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Occudo Quantitative Strategies's FATE Position: Q2 2023 in Review

Occudo Quantitative Strategies sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 98,452 shares — an estimated $561K sold.

Occudo Quantitative Strategies first reported a position in FATE in Q4 2020 and held it in 6 quarters. The position peaked at $2.3M in Q2 2022. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Occudo Quantitative Strategies reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 98,452 Fate Therapeutics shares in Q2 2023, an estimated $561K.
  • Occudo Quantitative Strategies first reported a position in Fate Therapeutics in Q4 2020 and held it in 6 quarters.
  • Occudo Quantitative Strategies's Fate Therapeutics position peaked at $2.3M in Q2 2022.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.